[go: up one dir, main page]

ATE246197T1 - Neue heteroaromatische fructose 1,6- bisphosphatase inhibitoren - Google Patents

Neue heteroaromatische fructose 1,6- bisphosphatase inhibitoren

Info

Publication number
ATE246197T1
ATE246197T1 AT99954595T AT99954595T ATE246197T1 AT E246197 T1 ATE246197 T1 AT E246197T1 AT 99954595 T AT99954595 T AT 99954595T AT 99954595 T AT99954595 T AT 99954595T AT E246197 T1 ATE246197 T1 AT E246197T1
Authority
AT
Austria
Prior art keywords
fructose
bisphosphatase inhibitors
new heteroaromatic
heteroaromatic
new
Prior art date
Application number
AT99954595T
Other languages
English (en)
Inventor
Qun Dang
Srinivas Rao Kasibhatla
K Raja Reddy
Mark D Erion
M Rami Reddy
Atul Agarwal
Original Assignee
Metabasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabasis Therapeutics Inc filed Critical Metabasis Therapeutics Inc
Application granted granted Critical
Publication of ATE246197T1 publication Critical patent/ATE246197T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/653—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/653—Five-membered rings
    • C07F9/65324—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings
    • C07F9/65392—Five-membered rings containing two nitrogen atoms
    • C07F9/65395—Five-membered rings containing two nitrogen atoms having the two nitrogen atoms in positions 1 and 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings
    • C07F9/6541—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
    • C07F9/655345—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/657163—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
    • C07F9/657181—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom the ring phosphorus atom and, at least, one ring oxygen atom being part of a (thio)phosphonic acid derivative
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6578—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and sulfur atoms with or without oxygen atoms, as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
    • C07F9/65846—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a six-membered ring which may be condensed with another ring system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT99954595T 1998-09-09 1999-09-03 Neue heteroaromatische fructose 1,6- bisphosphatase inhibitoren ATE246197T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13550498P 1998-09-09 1998-09-09
US11107798P 1998-12-07 1998-12-07
PCT/US1999/020346 WO2000014095A1 (en) 1998-09-09 1999-09-03 Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase

Publications (1)

Publication Number Publication Date
ATE246197T1 true ATE246197T1 (de) 2003-08-15

Family

ID=26808618

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99954595T ATE246197T1 (de) 1998-09-09 1999-09-03 Neue heteroaromatische fructose 1,6- bisphosphatase inhibitoren

Country Status (21)

Country Link
US (4) US6489476B1 (de)
EP (1) EP1112275B9 (de)
JP (1) JP2002524463A (de)
KR (2) KR20070053264A (de)
CN (1) CN1215076C (de)
AT (1) ATE246197T1 (de)
AU (1) AU761267C (de)
BR (1) BR9913532A (de)
CA (1) CA2343027A1 (de)
CZ (1) CZ297264B6 (de)
DE (1) DE69910045T2 (de)
DK (1) DK1112275T3 (de)
ES (1) ES2204170T3 (de)
HK (1) HK1042496B (de)
HU (1) HUP0103143A3 (de)
NO (1) NO20011174L (de)
NZ (1) NZ510308A (de)
PL (1) PL205184B1 (de)
PT (1) PT1112275E (de)
SK (1) SK286080B6 (de)
WO (1) WO2000014095A1 (de)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6452098A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
PL205184B1 (pl) * 1998-09-09 2010-03-31 Metabasis Therapeutics Inc Nowe heteroaromatyczne inhibitory 1,6-bisfosfatazy fruktozy, kompozycje farmaceutyczne zawierające te związki i ich zastosowanie
US6756360B1 (en) * 1998-12-24 2004-06-29 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
JP5063837B2 (ja) * 1999-03-05 2012-10-31 リガンド・ファーマシューティカルズ・インコーポレイテッド 新規リン含有プロドラッグ
US7205404B1 (en) * 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
CA2396713A1 (en) * 1999-12-22 2001-07-05 Metabasis Therapeutics, Inc. Novel bisamidate phosphonate prodrugs
PT1741445E (pt) 2000-01-21 2013-11-11 Novartis Ag Combinações incluindo inibidores de dipeptidilpeptidase-iv e agentes antidiabéticos
AU4553201A (en) 2000-03-08 2001-09-17 Metabasis Therapeutics Inc Novel aryl fructose-1,6-bisphosphatase inhibitors
US7563774B2 (en) * 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
RU2328308C2 (ru) * 2000-07-06 2008-07-10 Метабэйсис Терапьютикс, Инк. Комбинирование ингибиторов fbp-азы и антидиабетических средств для лечения диабета
US20070129334A1 (en) * 2001-10-30 2007-06-07 Conforma Therapeutics Corporation Orally Active Purine-Based Inhibitors of Heat Shock Protein 90
CA2485702C (en) * 2002-05-13 2011-07-19 Metabasis Therapeutics, Inc. Novel phosphonic acid based prodrugs of pmea and its analogues
JP4332496B2 (ja) * 2002-05-13 2009-09-16 メタバシス・セラピューティクス・インコーポレイテッド Ｐｍｅａおよびｐｍｐａ環生成合成
TW200409643A (en) * 2002-07-23 2004-06-16 Sankyo Co Preventive agents for diabetes mellitus
CA2503730C (en) * 2002-10-31 2011-10-18 Metabasis Therapeutics, Inc. Cytarabine monophosphate prodrugs
US20040254228A1 (en) * 2002-12-20 2004-12-16 Lin Zhao Treatment of chronic heart failure
US20040122067A1 (en) * 2002-12-20 2004-06-24 Lin Zhao Treatment of chronic heart failure
US7705027B2 (en) * 2003-02-11 2010-04-27 Vernalis (Cambridge) Limited Isoxazole compounds as inhibitors of heat shock proteins
BRPI0416639A (pt) 2003-11-19 2007-01-16 Metabasis Therapeutics Inc tiromiméticos contendo fósforo
US7129049B2 (en) * 2003-12-22 2006-10-31 Regents Of The University Of Minnesota Method of detecting equine glycogen storage disease IV
SI3002283T1 (en) 2003-12-26 2018-06-29 Kyowa Hakko Kirin Co., Ltd. Thiazole derivatives
AU2005230846A1 (en) * 2004-03-31 2005-10-20 Lexicon Pharmaceuticals, Inc. 2-aminomethylthiazole-5-carboxamides as protein kinase modulators
JP2007261945A (ja) * 2004-04-07 2007-10-11 Taisho Pharmaceut Co Ltd チアゾール誘導体
MXPA06014013A (es) * 2004-06-08 2007-03-15 Metabasis Therapeutics Inc Sintesis mediada por acidos de lewis de esteres ciclicos.
CN101005847A (zh) * 2004-08-18 2007-07-25 症变治疗公司 果糖1,6－双磷酸酶的新颖噻唑类抑制剂
CN101119748A (zh) * 2004-12-13 2008-02-06 第一三共株式会社 用于治疗糖尿病的药物组合物
WO2006064826A1 (ja) * 2004-12-15 2006-06-22 Daiichi Sankyo Company, Limited FBPase阻害剤を含有する医薬組成物
WO2008134474A2 (en) 2007-04-27 2008-11-06 The Board Of Trustees Of The University Of Illinois Compositions and methods including cell death inducers and procaspase activation
JPWO2006137527A1 (ja) 2005-06-23 2009-01-22 協和発酵キリン株式会社 チアゾール誘導体
EP1752450A1 (de) 2005-08-01 2007-02-14 Merck Sante Imidazolderivate als Fruktose-1,6-biphosphataseinhibitoren und pharmazeutische Zusammensetzungen diese enthaltend
FR2889190A1 (fr) * 2005-08-01 2007-02-02 Merck Sante Soc Par Actions Si Nouveaux derives d'imidazoles carboxamides comme inhibiteurs de fructose -1,6-biphosphatase et compositions pharmaceutiques les contenant
HRP20140091T4 (hr) 2005-09-14 2021-12-24 Takeda Pharmaceutical Company Limited Davanje inhibitora dipeptidil peptidaze
KR20090020585A (ko) 2006-05-19 2009-02-26 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 흑색종 및 기타암 치료용 트리페닐메틸포스포네이트 에스테르 함유 포스포러스 화합물
WO2008057933A2 (en) * 2006-11-02 2008-05-15 Aestus Therapeutics, Inc. Methods of treating neuropathic pain by modulation of glycogenolysis or glycolysis pathways
US20080218127A1 (en) * 2007-03-07 2008-09-11 O2Micro Inc. Battery management systems with controllable adapter output
US7973515B2 (en) * 2007-03-07 2011-07-05 O2Micro, Inc Power management systems with controllable adapter output
US8222870B2 (en) * 2007-03-07 2012-07-17 O2Micro, Inc Battery management systems with adjustable charging current
MX2010001784A (es) 2007-08-13 2010-03-15 Metabasis Therapeutics Inc Activadores novedosos de la glucocinasa.
EP2058308A1 (de) 2007-11-12 2009-05-13 Merck Sante Benzimidazoldihydrothiadiazinonderivate als Fructose-1,6-biphosphatase-Hemmer und diese enthaltende pharmazeutische Zusammensetzungen.
US8111038B2 (en) * 2008-06-12 2012-02-07 O2 Micro, Inc Vehicle electronic systems with battery management functions
CA2737694C (en) 2008-09-26 2013-07-02 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
MX2011004258A (es) 2008-10-22 2011-06-01 Merck Sharp & Dohme Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos.
AU2009309007A1 (en) 2008-10-29 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
JO2870B1 (en) 2008-11-13 2015-03-15 ميرك شارب اند دوهم كورب Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
US8759539B2 (en) 2008-11-17 2014-06-24 Merck Sharp & Dohme Corp. Substituted bicyclic amines for the treatment of diabetes
US8778945B2 (en) 2009-02-09 2014-07-15 The Board Of Trustees Of The University Of Illinois Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
EP3366686B9 (de) 2009-03-20 2021-08-04 Metabasis Therapeutics, Inc. Inhibitoren von diacylglycerin-o-acyltransferase 1 (dgat-1) und verwendungen davon
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
CA2768577A1 (en) 2009-07-23 2011-01-27 Schering Corporation Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
WO2011019538A1 (en) 2009-08-13 2011-02-17 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
JP5734981B2 (ja) 2009-09-02 2015-06-17 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病の治療又は予防のためのジペプチジルペプチダーゼｉｖ阻害剤としてのアミノテトラヒドロピラン
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
CN102834393B (zh) 2010-02-03 2015-07-22 武田药品工业株式会社 细胞凋亡信号调节激酶1抑制剂
EP2538783B1 (de) 2010-02-22 2016-06-01 Merck Sharp & Dohme Corp. Substituierte aminotetrahydrothiopyrane als dipeptidylpeptidase-iv-hemmer zur behandlung von diabetes
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8980929B2 (en) 2010-05-21 2015-03-17 Merck Sharp & Dohme Corp. Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
WO2012024183A1 (en) 2010-08-18 2012-02-23 Merck Sharp & Dohme Corp. Spiroxazolidinone compounds
MX2013009551A (es) * 2011-02-24 2013-09-06 Jiangsu Hanson Pharmaceutical Co Ltd Compuestos que contienen fosforo como inhibidores de proteina cinasa.
WO2012116145A1 (en) 2011-02-25 2012-08-30 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
WO2012138845A1 (en) 2011-04-08 2012-10-11 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
CN103687855A (zh) 2011-06-02 2014-03-26 英特维特国际股份有限公司 咪唑衍生物
AU2012271009A1 (en) 2011-06-16 2013-11-14 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
EP2760855B1 (de) 2011-09-30 2017-03-15 Merck Sharp & Dohme Corp. Substituierte cyclopropylverbindungen, zusammensetzungen mit solchen verbindungen und ihre verwendung bei der behandlung von typ-2 diabetes
EP2771000B1 (de) 2011-10-24 2016-05-04 Merck Sharp & Dohme Corp. Substituierte piperidinylverbindungen als gpr119-agonisten
WO2013068328A1 (en) 2011-11-07 2013-05-16 Intervet International B.V. Bicyclo [2.2.2] octan-1-ylcarboxylic acid compounds as dgat-1 inhibitors
WO2013068439A1 (en) 2011-11-09 2013-05-16 Intervet International B.V. 4-amino-5-oxo-7,8-dihydropyrimido[5, 4 -f] [1, 4] oxazepine compounds as dgat1 inhibitors
WO2013074581A1 (en) * 2011-11-15 2013-05-23 Weihua Zhang Fructose-1,6-biphosphatases as new targets for diagnosing and treating breast cancer brain metastasis
EP2780337B1 (de) 2011-11-15 2017-12-20 Merck Sharp & Dohme Corp. Substituierte cyclopropylverbindungen als gpr119-agonisten
WO2013122920A1 (en) 2012-02-17 2013-08-22 Merck Sharp & Dohme Corp. Dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
IN2014DN09640A (de) 2012-04-16 2015-07-31 Kaneq Pharma Inc
WO2014018350A1 (en) 2012-07-23 2014-01-30 Merck Sharp & Dohme Corp. Treating diabetes with dipeptidyl peptidase-iv inhibitors
WO2014022528A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JP2015526468A (ja) 2012-08-22 2015-09-10 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 新規なアザベンズイミダゾールヘキサヒドロフロ［３，２−ｂ］フラン誘導体
ES2755087T3 (es) 2012-08-22 2020-04-21 Merck Sharp & Dohme Derivados de benzimidazol hexahidrofuro[3,2-b]furano útiles como activadores de proteína cinasa activada por AMP
WO2014031441A1 (en) 2012-08-22 2014-02-27 Merck Sharp & Dohme Corp. Novel benzimidazole tetrahydrofuran derivatives
WO2014031445A1 (en) 2012-08-22 2014-02-27 Merck Sharp & Dohme Corp. Novel benzimidazole tetrahydropyran derivatives
WO2014031465A1 (en) 2012-08-22 2014-02-27 Merck Sharp & Dohme Corp. Novel azabenzimidazole tetrahydropyran derivatives
EP2888008B1 (de) 2012-08-22 2018-12-26 Merck Sharp & Dohme Corp. Neuartige azabenzimidazol-tetrahydrofuranderivate
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
EP2931734B1 (de) 2012-12-17 2020-12-02 Merck Sharp & Dohme Corp. Neuartige glucokinase-aktivatorverbindungen, zusammensetzungen mit solchen verbindungen und behandlungsverfahren
EP2970119B1 (de) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Neuartige indolderivate als antidiabetika
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP3068768B1 (de) 2013-11-15 2019-07-31 Merck Sharp & Dohme Corp. Antidiabetische tricyclische verbindungen
WO2015089809A1 (en) 2013-12-19 2015-06-25 Merck Sharp & Dohme Corp. Antidiabetic substituted heteroaryl compounds
US10065945B2 (en) 2014-01-24 2018-09-04 Merck Sharp & Dohme Corp. Isoquinoline derivatives as MGAT2 inhibitors
EP3105238A4 (de) 2014-02-13 2017-11-08 Ligand Pharmaceuticals, Inc. Organische verbindungen und deren verwendungen
KR20160118368A (ko) 2014-02-25 2016-10-11 아칠리온 파르마세우티칼스 인코포레이티드 보체 매개된 장애의 치료를 위한 에터 화합물
WO2015176267A1 (en) 2014-05-22 2015-11-26 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JP2017520545A (ja) 2014-07-02 2017-07-27 リガンド・ファーマシューティカルズ・インコーポレイテッド プロドラッグ化合物およびそれらの使用
US10662171B2 (en) 2014-08-08 2020-05-26 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
EP3177287B1 (de) 2014-08-08 2022-02-23 Merck Sharp & Dohme Corp. Antidiabetische bicyclische verbindungen
WO2016022446A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [5,6]-fused bicyclic antidiabetic compounds
US10413593B2 (en) 2014-10-24 2019-09-17 Merck Sharp & Dohme Corp. Co-agonists of the glucagon and GLP-1 receptors
MY186702A (en) 2014-10-31 2021-08-11 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
TW201625635A (zh) 2014-11-21 2016-07-16 默沙東藥廠 作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物
WO2016191334A1 (en) 2015-05-27 2016-12-01 Merck Sharp & Dohme Corp. Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
EP3310782B1 (de) 2015-05-28 2021-12-01 Merck Sharp & Dohme Corp. Als lösliche guanylat-cyclase-aktivatoren geeignete imidazopyrazinylderivate
WO2017035357A1 (en) * 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of medical disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
AR105808A1 (es) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc Compuestos de amida para el tratamiento de trastornos médicos
WO2017035361A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Disubstituted compounds for the treatment of medical disorders
ES2908479T3 (es) 2015-08-26 2022-04-29 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos inmunitarios e inflamatorios
WO2017035351A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of medical disorders
US10385097B2 (en) 2015-08-26 2019-08-20 Achillion Pharmaceuticals, Inc. Ether compounds for treatment of medical disorders
EP3340983B1 (de) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl und heterocyclische verbindungen zur behandlung von immun- und entzündungserkrankungen
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
AR105809A1 (es) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos médicos
AU2016326397A1 (en) * 2015-09-22 2018-04-19 Viking Therapeutics, Inc. Conjoint therapies with inhibitors of glucose production
EP3359191A4 (de) 2015-10-05 2019-05-29 Merck Sharp & Dohme Corp. Antikörper-peptid-konjugate mit agonistenaktivität an rezeptoren von glucagon als auch glukagon-like peptid-1
WO2017095724A1 (en) 2015-11-30 2017-06-08 Merck Sharp & Dohme Corp. Aryl sulfonamides as blt1 antagonists
WO2017107052A1 (en) 2015-12-22 2017-06-29 Merck Sharp & Dohme Corp. Soluble guanylate cyclase stimulators
WO2017197555A1 (en) 2016-05-16 2017-11-23 Merck Sharp & Dohme Corp. Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators
WO2017201683A1 (en) 2016-05-25 2017-11-30 Merck Sharp & Dohme Corp. Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists
EP3496716B1 (de) 2016-08-15 2021-11-03 Merck Sharp & Dohme Corp. Verbindungen zur änderung der konzentrationen von gallensäuren zur behandlung von diabetes und kardiometabolischen erkrankungen
WO2018034917A1 (en) 2016-08-15 2018-02-22 Merck Sharp & Dohme Corp. Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease
WO2018057409A1 (en) 2016-09-20 2018-03-29 Merck Sharp & Dohme Corp. Substituted 1-methyl-1,2,3,4-tetrahydroisoquinoline molecules as pcsk9 allosteric binders
JP2020500192A (ja) 2016-11-18 2020-01-09 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ジアシルグリセリドｏ−アシルトランスフェラーゼ２の阻害薬として有用なインドール誘導体
BR112019010164A2 (pt) 2016-11-18 2019-09-17 Merck Sharp & Dohme composto, composição farmacêutica, uso de um composto, e, método para tratar aterosclerose, esteatose hepática, aterosclerose, diabetes mellitus tipo 2, obesidade, hiperlipidemia ou hipercolesterolemia.
WO2018107415A1 (en) 2016-12-15 2018-06-21 Merck Sharp & Dohme Corp. Hydroxy isoxazole compounds useful as gpr120 agonists
WO2018160892A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for treatment of medical disorders
EP3589628B1 (de) 2017-03-01 2025-05-07 Achillion Pharmaceuticals, Inc. Aryl-, heteroaryl- und heterocyclische verbindungen zur behandlung von medizinischen erkrankungen
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
WO2018175670A1 (en) 2017-03-22 2018-09-27 The Research Foundation For The State University Of New York Matrix metalloproteinase-9 hemopexin domain inhibitors and methods of treatment using same
EP3661493A4 (de) 2017-08-02 2021-04-14 Achillion Pharmaceuticals, Inc. Therapiepläne zur behandlung von paroxysmaler nächtlicher hämoglobinurie
AU2019207625A1 (en) 2018-01-09 2020-07-30 Ligand Pharmaceuticals, Inc. Acetal compounds and therapeutic uses thereof
JOP20190150A1 (ar) 2018-06-21 2019-12-21 Merck Sharp & Dohme مركبات مناهضة لـ pcsk9
BR112021004263A2 (pt) 2018-09-06 2021-05-25 Achillion Pharmaceuticals, Inc. formas mórficas de danicopano
WO2020051532A2 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
MX2021003425A (es) 2018-09-25 2021-07-16 Achillion Pharmaceuticals Inc Formas morficas de los inhibidores del factor d del complemento.
JP7471300B2 (ja) 2018-12-17 2024-04-19 アキリオン ファーマシューティカルズ， インコーポレーテッド 補体介在性疾患を治療するための的を絞った投与
EP3941462A4 (de) 2019-03-22 2023-04-05 Achillion Pharmaceuticals, Inc. Pharmazeutische verbindungen zur behandlung von komplementvermittelten erkrankungen
KR102691198B1 (ko) 2019-03-28 2024-08-05 백동민 로봇청소기 및 그 제어방법
EP3946324B1 (de) 2019-04-04 2025-07-30 Merck Sharp & Dohme LLC Inhibitoren von histon-deacetylase-3 zur behandlung von krebs, entzündung, neurodegenerativen erkrankungen und diabetes
US11484565B2 (en) 2019-08-30 2022-11-01 Merck Sharp & Dohme Llc PCSK9 antagonist compounds
EP3842449A1 (de) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Geklammerte olefin-co-agonisten der glucagon- und glp-1-rezeptoren
EP3842061A1 (de) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Geheftete triazol-co-agonisten der glucagon- und glp-1-rezeptoren
EP3842060A1 (de) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Geheftete lactam-co-agonisten der glucagon- und glp-1-rezeptoren
US20230174521A1 (en) 2020-05-18 2023-06-08 Merck Sharp & Dohme Llc Novel diacylglyceride o-acyltransferase 2 inhibitors
CA3195014A1 (en) 2020-10-08 2022-04-14 Yeon-Hee Lim Preparation of benzimidazolone derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors
CN116457346A (zh) 2020-10-08 2023-07-18 默沙东有限责任公司 作为新型二酰基甘油酯o-酰基转移酶2抑制剂的吲哚酮衍生物的制备
AU2022330007A1 (en) 2021-08-19 2024-02-15 Merck Sharp & Dohme Llc Compounds for treating conditions related to pcsk9 activity
US20230406885A1 (en) 2022-06-15 2023-12-21 Merck Sharp & Dohme Llc Cyclic peptides for trapping interleukin-1 beta
GEAP202516792A (en) 2022-12-02 2025-10-10 Merck Sharp & Dohme Llc Preparation of fused azole derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors
CN117486955A (zh) * 2023-10-17 2024-02-02 上海交通大学 一种非经典c-糖苷及其立体专一性合成方法和应用
TW202540146A (zh) 2023-11-14 2025-10-16 美商默沙東有限責任公司 用於捕捉介白素－１ β之環狀肽
TW202542176A (zh) 2023-12-15 2025-11-01 美商默沙東有限責任公司 用於治療動脈粥樣硬化及發炎病症之環狀肽IL-1β捕捉劑
WO2026019977A1 (en) 2024-07-19 2026-01-22 Merck Sharp & Dohme Llc Pyrrolopyridazine vegfr inhibitors

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR34480E (de) 1929-01-17 1929-06-19
US3551422A (en) 1968-03-27 1970-12-29 Stevens & Co Inc J P N-(oxymethyl) derivatives of phosphonopolyamino-s-triazines
US3822296A (en) * 1969-01-23 1974-07-02 Merck & Co Inc 1-trifluoromethyl-1,2-epoxyethyl-1-phosphonic acid and its salts
US3657282A (en) * 1969-01-23 1972-04-18 Merck & Co Inc Carboxyepoxyethyl-1-phosphonic acid and derivatives
GB1343022A (en) 1970-04-19 1974-01-10 British Oxygen Co Ltd Phosphorus-containing guanamines
GB1428137A (en) 1972-09-27 1976-03-17 Ici Ltd Prostanoic acid derivatives
US4000305A (en) * 1972-09-27 1976-12-28 Imperial Chemical Industries Limited 15-, 16- AND 17-Indolyl or indolinyl nor prostanoic acid derivatives
GB1516347A (en) 1975-09-16 1978-07-05 Ici Ltd Process for the preparation of alkylphosphonate esters
US4092323A (en) 1975-09-16 1978-05-30 Imperial Chemical Industries Limited Hydrazine derivatives of pyridyl-ketones
DE2855659A1 (de) 1978-12-22 1980-07-03 Bayer Ag Benzimidazolyl-2-alkan-phosphonsaeuren
DE3173080D1 (en) 1980-01-10 1986-01-16 Nyegaard & Co As Pyrimidine-2-sulphides and their s-oxides for use in medicine, pharmaceutical compositions containing them, processes for their preparation and such compounds when novel per se
FR2531088B1 (fr) * 1982-07-29 1987-08-28 Sanofi Sa Produits anti-inflammatoires derives de l'acide methylenediphosphonique et leur procede de preparation
IL77243A (en) 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
US4902679A (en) 1985-12-13 1990-02-20 Norwich Eaton Pharmaceuticals, Inc. Methods of treating diseases with certain geminal diphosphonates
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
ES2039237T3 (es) 1986-04-24 1993-09-16 Fujisawa Pharmaceutical Co., Ltd. Procedimiento para preparar nuevos compuestos de acido difosfonico.
JPS636089A (ja) 1986-06-27 1988-01-12 Nippon Shokubai Kagaku Kogyo Co Ltd 石炭−水スラリ−用分散剤
US5091552A (en) 1986-06-30 1992-02-25 Board Of Regents, The University Of Texas System Novel antitumor aldophosphamide analogs
ATE72816T1 (de) 1986-11-21 1992-03-15 Ciba Geigy Ag Neue substituierte alkandiphosphonsaeuren.
JPS63250290A (ja) 1987-04-06 1988-10-18 Matsushita Electric Ind Co Ltd 電子スチルカメラ
US4912175A (en) 1988-08-01 1990-03-27 E. I. Du Pont De Nemours And Company Process for in creasing polyamide molecular weight with P containing catalyst
US4943629A (en) * 1988-08-12 1990-07-24 American Cyanamid Company Antidiabetic alpha-substituted phosphonates
US4968790A (en) 1988-08-12 1990-11-06 American Cyanamid Company Antidiabetic phosphates
DK0427799T3 (da) 1989-01-24 1995-05-08 Gensia Inc Fremgangsmåde og forbindelser til indgivelse af AICA-ribosid og til nedsættelse af blodglucose
US5658889A (en) * 1989-01-24 1997-08-19 Gensia Pharmaceuticals, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
MX21452A (es) * 1989-07-07 1994-01-31 Ciba Geigy Ag Preparaciones farmaceuticas que se administran en forma topica.
DE4029444A1 (de) 1989-09-19 1991-03-28 Ciba Geigy Ag Phosphonyl-enamine als pflanzenwuchsregulatoren
EP0438375B1 (de) 1990-01-18 1995-12-27 Ciba-Geigy Ag Phoshponsäure- und Thionophosphonsäure-Derivate
US5116919A (en) 1990-12-05 1992-05-26 E. I. Du Pont De Nemours And Company Process for increasing the relative viscosity of polyamides with reduced thermal degradation
FI89366C (fi) 1990-12-20 1993-09-27 Leiras Oy Foerfarande foer framstaellning av nya farmakologiskt anvaendbara metylenbisfosfonsyraderivat
US5194616A (en) 1991-01-24 1993-03-16 E. I. Du Pont De Nemours And Company Preparation of 2-(pyridyl)ethyl bis-(trialkyl silyl)phosphonate derivatives
JPH06507156A (ja) 1991-04-27 1994-08-11 日本チバガイギー株式会社 トリアゾール化合物
EP0528760A1 (de) 1991-08-09 1993-02-24 Japat Ltd Neue Triazole
US5142000A (en) 1991-08-28 1992-08-25 E. I. Du Pont De Nemours And Company Process for increasing polyamide molecular weight with organophosphonic acid or ester catalysts in the presence of alumina-containing titanium dioxide
US5302586A (en) * 1991-12-19 1994-04-12 G. D. Searle & Co. Phosphonomethyl-imidazo[1,2-a]pyrimidine-2-carboxylic acid compounds for treatment of neurotoxic injury
MX9300141A (es) 1992-01-13 1994-07-29 Smithkline Beecham Corp Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
GB9202779D0 (en) 1992-02-10 1992-03-25 Ici Plc Novel compounds
CH683996A5 (fr) 1992-03-05 1994-06-30 Symphar Sa Dérivés aminophosphonates substitués, leur procédé de préparation et compositions pharmaceutiques les contenant.
US5731299A (en) 1992-05-29 1998-03-24 The Procter & Gamble Company Phosphonosulfonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism
JP2787407B2 (ja) 1992-06-19 1998-08-20 株式会社大塚製薬工場 ホスホン酸ジエステル誘導体
NZ254550A (en) * 1992-09-28 1997-08-22 Pfizer Use of nitrogen-substituted pyrimidines to prepare medicaments useful for treatment or prevention of diabetic complications
GB2271113A (en) 1992-10-02 1994-04-06 Japat Ltd Triazolyl alkyl phosphates or phosphonates
DE4303648A1 (de) 1993-02-09 1994-08-11 Basf Ag Verwendung von Aminovinylphosphonsäureestern als Lichtschutzmittel und Stabilisatoren für organisches Material
JPH06298779A (ja) 1993-04-15 1994-10-25 Hoechst Japan Ltd ヘテロ環イミノビスメチレンビスホスホン酸誘導体
ATE199906T1 (de) 1993-06-29 2001-04-15 Mitsubishi Chem Corp Phosphonat-nukleotid ester-derivate
IT1266570B1 (it) 1993-07-30 1997-01-09 Zambon Spa Derivati della propanammide n-eteroaril sostituiti utili nel trattamento delle malattie cardiovascolari
BR9407510A (pt) 1993-09-17 1997-01-07 Gilead Sciences Inc Análogos de nucleotideo
US5728650A (en) 1993-10-07 1998-03-17 Zeneca Limited Herbicidal aza bisphosphonic acids and compositions containing the same
GB9324143D0 (en) 1993-11-24 1994-01-12 Schering Agrochemicals Ltd Triazole phosphonate pesticides
DE19501843A1 (de) 1994-12-16 1996-06-20 Bayer Ag Substituierte Sulfonylharnstoffe
AU702980B2 (en) 1995-12-27 1999-03-11 Otsuka Pharmaceutical Factory, Inc. Phosphonic diester derivatives
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
US6011049A (en) 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
AU6452098A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
WO1998039342A1 (en) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
ZA981936B (en) 1997-03-07 1999-09-06 Metabasis Therapeutics Inc Novel benzimidazole inhibitors of fructose 1,6-bisphosphatase.
US6312662B1 (en) * 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
AU767599B2 (en) 1998-03-06 2003-11-20 Metabasis Therapeutics, Inc. Novel prodrugs for phosphorus-containing compounds
US6107274A (en) 1998-03-16 2000-08-22 Ontogen Corporation Piperazines as inhibitors of fructose-1,6-bisphosphatase (FBPase)
PL205184B1 (pl) * 1998-09-09 2010-03-31 Metabasis Therapeutics Inc Nowe heteroaromatyczne inhibitory 1,6-bisfosfatazy fruktozy, kompozycje farmaceutyczne zawierające te związki i ich zastosowanie
EP1143955B1 (de) 1998-12-24 2005-07-27 Metabasis Therapeutics, Inc. Zusammensetzung enthaltend insulin-sensibilisierenden wirkstoffe und inhibitoren der fruktose-1,6-bisphosphatase (fbpase) zur behandlung von diabetes
US6756360B1 (en) 1998-12-24 2004-06-29 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
US6284672B1 (en) * 1999-03-02 2001-09-04 Advanced Micro Devices, Inc. Method of forming a super-shallow amorphous layer in silicon
CA2396713A1 (en) 1999-12-22 2001-07-05 Metabasis Therapeutics, Inc. Novel bisamidate phosphonate prodrugs
PT1741445E (pt) 2000-01-21 2013-11-11 Novartis Ag Combinações incluindo inibidores de dipeptidilpeptidase-iv e agentes antidiabéticos
AU4553201A (en) 2000-03-08 2001-09-17 Metabasis Therapeutics Inc Novel aryl fructose-1,6-bisphosphatase inhibitors
US7563774B2 (en) 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
RU2328308C2 (ru) 2000-07-06 2008-07-10 Метабэйсис Терапьютикс, Инк. Комбинирование ингибиторов fbp-азы и антидиабетических средств для лечения диабета
CN101005847A (zh) 2004-08-18 2007-07-25 症变治疗公司 果糖1,6－双磷酸酶的新颖噻唑类抑制剂

Also Published As

Publication number Publication date
US20070232571A1 (en) 2007-10-04
PT1112275E (pt) 2003-12-31
WO2000014095A1 (en) 2000-03-16
US7312219B2 (en) 2007-12-25
HUP0103143A3 (en) 2003-01-28
JP2002524463A (ja) 2002-08-06
AU1090500A (en) 2000-03-27
CZ297264B6 (cs) 2006-10-11
BR9913532A (pt) 2001-10-02
DE69910045D1 (de) 2003-09-04
US20040058892A1 (en) 2004-03-25
KR20070053264A (ko) 2007-05-23
SK286080B6 (sk) 2008-03-05
SK3162001A3 (en) 2002-02-05
CN1326459A (zh) 2001-12-12
HK1042496A1 (en) 2002-08-16
AU761267C (en) 2007-08-09
EP1112275B9 (de) 2004-03-10
DK1112275T3 (da) 2003-11-24
CA2343027A1 (en) 2000-03-16
NO20011174D0 (no) 2001-03-07
DE69910045T2 (de) 2004-04-22
PL346520A1 (en) 2002-02-11
NO20011174L (no) 2001-05-09
CZ2001840A3 (cs) 2001-09-12
KR100818845B1 (ko) 2008-04-01
HUP0103143A2 (hu) 2002-04-29
US6489476B1 (en) 2002-12-03
EP1112275B1 (de) 2003-07-30
EP1112275A1 (de) 2001-07-04
KR20010085776A (ko) 2001-09-07
HK1042496B (zh) 2006-01-27
US20080015195A1 (en) 2008-01-17
ES2204170T3 (es) 2004-04-16
PL205184B1 (pl) 2010-03-31
CN1215076C (zh) 2005-08-17
AU761267B2 (en) 2003-05-29
NZ510308A (en) 2003-06-30

Similar Documents

Publication Publication Date Title
ATE246197T1 (de) Neue heteroaromatische fructose 1,6- bisphosphatase inhibitoren
MXPA02008722A (es) Inhibidores novedosos de aril fructosa-1,6-bisfosfatasa.
HK1049841A1 (zh) 新瞵酸二酰胺药物前体
DE69633679D1 (de) Substituierte aryl-oder heteroarylamide mit retinoid-ähnlicher biologischer aktivität
MY180762A (en) Combination therapy comprising glucose reabsorption inhibitors and ppar modulators.
PT1349856E (pt) Compostos de isoindolina-1-ona activadores da glicocinase
BR9814189A (pt) "compostos agonistas da exendina"
BR9814361A (pt) Inibição de quinase raf usando uréiasheterocìclicas substituìdas por arila eheteroarila
GB0213612D0 (en) Organic compounds
TR200103493T2 (tr) Metaloproteaz önleyicileri
EP0986382A4 (de) Raf kinase hemmer
BR9913517A (pt) Composição, dispositivo, e, uso de uma composição
DK1053256T3 (da) Antistoffer mod Dødsreceptor 4 (DR4) og anvendelser deraf
ATE320457T1 (de) Polyurethanlösungen mit alkoxysilanstruktureinheiten
DE69919179D1 (de) Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
ATE196083T1 (de) Verwendung von ferrioxamin-b zur behandlung septischen schocks
TR200001288T2 (tr) Östrojen yoksunluğu sendromunun tedavisinde faydalı 2-arilbenzo (b) tiyofenler.
TR200001102T2 (tr) İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.
DE3765808D1 (de) Heterocyclische tetrahydro-3,4-diamin-n-n'-platin-komplexe.
DK1100824T3 (da) Forbindelser med væksthormonfrigivende egenskaber
EA199900579A1 (ru) Применение ингибиторов комт для производства лекарственного средства для профилактики сосудистых дисфункций при диабете
WO2003017925A3 (en) Treatment of type i diabetes
TR199701605A2 (xx) S�lfonamid-substit�e edilmi� bile�ikler
DE69807200D1 (de) Inklusionskomplexe in waessriger loesung
WO2001000188A3 (de) Tetrahydrochinolinyl-6-methyldihydrothiadiazinon-derivate ind ihre verwendung zur prophylaxe und/oder behandlung von anämien

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1112275

Country of ref document: EP